Back

SGLT2i is indicated for all HFpEF patients - pro.

23 May 2022 (08:30 - 08:50)
Organised by:
Congress Presentation Part of: SGLT2i for HFpEF Chronic Heart Failure HFA Premium Access Heart Failure 2022

About the speaker

Photo
Professor Andrew Stewart Coats

Heart Research Institute, Sydney (Australia)

2 More presentations in this session

Presentation thumbnail
SGLT2i is indicated for all HFpEF patients - con.
Professor S. Harikrishnan (Thiruvananthapuram, IN)
Slides Video
Presentation thumbnail
SGLT2i for HFpEF - rebuttal and discussion.
Video

Access the full session

Session thumbnail
SGLT2i for HFpEF
Video

The Event

Event poster

Heart Failure 2022

23 May 2022 08:30 CET
You may be interested in
thumbnail
Congress Session
SGLT2 inhibitors across the spectrum of heart failure
21 May 2022
thumbnail
Congress Presentation
When EF may no longer be relevant
22 May 2023
thumbnail
Congress Presentation
Heart failure with 'preserved' EF: what is a 'preserved' EF and how should I treat these patients?
28 August 2022
thumbnail
Congress Presentation
A patient with HF and LVEF > 40%: SGLT2 inhibitors.
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources